Sensorion will participate in the 2nd Annual LifeSci Partners Genetic Medicines Symposium on June 29, 2022

MONTPELLIER, France, June 24, 2022–(COMMERCIAL WIRE)–Regulatory information:

Sensorion (FR0012596468 – ALSEN) (Paris: ALSEN), a pioneering clinical-stage biotechnology firm specializing within the growth of recent therapies to revive, deal with and stop inside the subject of listening to loss issues, is happy to announce the participation of CEO Nawal Ouzren in LifeSci companions 2North Dakota Annual Genetic Medicines Symposium to be held nearly June 28-29, 2022.

CEO Nawal Ouzren will take part in a fireplace chat with Jeff Goodenbour as a part of the LifeSci 2 CompanionsNorth Dakota Annual Symposium on Genetic Medicineson June 29, 2022. To attend the dialogue, please register right here. A hearth chat replay will likely be out there shortly after the chat efficiency ends Hyperlink.

Date: Wednesday, June 29, 2022
dwelling To speak: 8:30 – 9:00 EST (14:30 – 15:00 CEST)
Occasion: LifeSci 2 CompanionsNorth Dakota Annual Symposium on Genetic Medicines

About Sensorion

Sensorion is a pioneering clinical-stage biotechnology firm specializing within the growth of novel therapies to revive, deal with and stop listening to loss issues, a major international unmet medical want.

Sensorion has created a singular R&D know-how platform to additional its understanding of the pathophysiology and etiology of internal ear-related ailments, enabling it to pick the very best targets and modalities for drug candidates. Its portfolio combines small molecule packages and a preclinical portfolio of internal ear gene therapies.

Its clinical-stage pipeline features a Section 2 product: SENS-401 (Arazasetron) advancing a deliberate Section 2 proof-of-concept medical examine of SENS-401 in cisplatin-induced ototoxicity (CIO) and, with associate Cochlear Restricted, a examine of SENS-401 in sufferers scheduled for cochlear implantation.

Sensorion has entered right into a broad strategic collaboration with the Institut Pasteur targeted on the genetics of listening to. Has two gene remedy packages geared toward correcting monogenic inherited types of deafness, together with deafness brought on by a mutation within the gene that codes for Otoferlin, and listening to loss associated to mutation within the GJB2 gene to handle doubtlessly necessary segments of listening to loss in adults and kids. The Firm can also be engaged on the identification of biomarkers to enhance the prognosis of those uncared for ailments.

www.sensorion.es

Label: SENSORION
IS IN: FR0012596468
Mnemonic: ALSEN

Disclaimer

This press launch incorporates sure forward-looking statements about Sensorion and its enterprise. Such forward-looking statements are primarily based on assumptions that Sensorion believes are cheap. Nonetheless, there could be no assure that such forward-looking statements will likely be verified, such statements are topic to quite a few dangers, together with the dangers set forth within the full 12 months 2021 monetary report printed on April 28, 2022 and out there on our web site and at growth of financial circumstances, monetary markets and markets by which Sensorion operates. The forward-looking statements contained on this press launch are additionally topic to dangers that Sensorion doesn’t but learn about or that Sensorion doesn’t presently think about to be important. The prevalence of all or a part of such dangers may trigger Sensorion’s precise outcomes, monetary situation, efficiency or achievements to vary materially from such forward-looking statements. This press launch and the knowledge it incorporates don’t represent a suggestion to promote or subscribe for, or a solicitation of a suggestion to purchase or subscribe for, Sensorion shares in any nation. Communication of this press launch in sure international locations could represent a violation of native legal guidelines and laws. All recipients of this press launch ought to inform themselves of and adjust to such native restrictions.

View the supply model on businesswire.com: https://www.businesswire.com/information/dwelling/20220623005695/en/

contacts

Investor Relations
catherine leveau
Head of Investor Relations and Communication
+33 6 72 18 00 22
ir.contact@sensorion-pharma.com

Worldwide Media Relations
Consilium Strategic Communications
Mary-Jane Elliott/Jessica Hodgson
+44 7739 788014
+44 7561 424788
Sensorion@consilium-comms.com

Leave a Comment